Retatrutide vs Mounjaro vs Ozempic: Triple, Dual and Single Agonists Explained

Is retatrutide the same as Mounjaro or Ozempic? No. Mounjaro is the brand name of tirzepatide, and Ozempic is a brand name of semaglutide. Both are approved prescription medicines. Retatrutide is a different, newer molecule that has finished its main Phase 3 trials but is not yet approved anywhere.

The names get mixed up in forums and searches, so this guide sorts them out: which is which, how one, two and three receptor agonists differ, and what the trials found. Everything here is for education and laboratory research only. It does not describe how to use, dose or treat anything with these compounds, and research material is not for human use.

Key Takeaways

• Mounjaro is tirzepatide, an FDA-approved prescription drug, and Ozempic and Wegovy are semaglutide, also FDA-approved prescription drugs. Retatrutide (LY3437943) is an investigational compound, not an approved medicine.
• The core difference is how many receptors each switches on: semaglutide is a single agonist (GLP-1), tirzepatide is a dual agonist (GLP-1 and GIP), and retatrutide is a triple agonist (GLP-1, GIP and glucagon).
• In its Phase 3 TRIUMPH-1 trial, retatrutide 12 mg cut body weight by 25.0% at 80 weeks, against 3.9% on placebo. Its Phase 2 work also showed liver fat falling by about 82%.
• Research peptides such as retatrutide are for laboratory study only. They are not substitutes for prescription medicines and are not Mounjaro, Ozempic or Wegovy.
• Retatrutide has CAS number 2381089-83-2, a molecular weight near 4731.41, and a design that binds albumin in the blood, giving it a half-life of about six days.
• For research-grade material, third-party HPLC testing, a published certificate of analysis (COA), and verified 99 percent-plus purity are the only meaningful trust signals.

Drugs Versus Research Compounds: The Distinction That Matters Most

The most important point in any "retatrutide vs Mounjaro" or "retatrutide vs Ozempic" comparison is legal status, because it changes what each substance is.

Mounjaro is the brand name for tirzepatide, approved by the FDA for type 2 diabetes. The same molecule is sold as Zepbound for weight management. Ozempic is the brand name for semaglutide, approved for type 2 diabetes, and the same molecule is sold as Wegovy for weight management. These are finished pharmaceutical products, manufactured under prescription-drug controls and dispensed by licensed providers.

Retatrutide is none of those. It is a three-receptor molecule from Eli Lilly that has completed its main Phase 3 trials, and Lilly plans to ask the FDA for approval in early 2027. Retatrutide sold as a research peptide is a laboratory reference compound, not a drug and not a copy of any approved medicine. Researchers studying gut-hormone biology buy it the way they buy any reference compound: to run experiments, not to treat anyone. Lyze Labs supplies retatrutide on exactly that basis, and the same goes for our tirzepatide and semaglutide kits.

Single, Dual, Triple: How the Mechanisms Differ

The clearest way to compare these molecules is by the receptors they switch on. Each extra receptor widens the metabolic pathways the compound can affect in research models.

Semaglutide (single agonist). Semaglutide switches on the GLP-1 receptor only. In research models, GLP-1 slows how fast the stomach empties, releases insulin when blood sugar is high, lowers glucagon and quiets food-seeking signals. It is the most established of the three, with the strongest heart data: the SELECT trial found about 20% fewer heart attacks, strokes and heart deaths (Lincoff, 2023).

Tirzepatide (dual agonist). Tirzepatide adds the GIP receptor to GLP-1. The GIP side seems to change how the body handles insulin and fat in ways that add to GLP-1. In the 2025 SURMOUNT-5 head-to-head trial, tirzepatide cut body weight by 20.2% against 13.7% for semaglutide at 72 weeks (Aronne, 2025).

Retatrutide (triple agonist). Retatrutide switches on all three: GLP-1, GIP and glucagon (GCGR). The glucagon receptor is what sets it apart. GLP-1 and GIP work mostly on appetite and insulin, while the glucagon receptor is linked to burning more energy and to the liver burning fat. The liver is packed with glucagon receptors, which is why liver scans in the Phase 2 work showed such large drops in liver fat. See the retatrutide kit for specifications.

Side-by-Side Research Comparison

The table sums up the published research and legal status of all three. The weight figures come from clinical trials.

What the Glucagon Receptor Adds in Research Models

Researchers studying retatrutide care most about the glucagon part because it changes the mechanism. In obese mice, retatrutide lowered body weight through two routes at once: the GLP-1 and GIP parts cut food intake, and the glucagon part raised the energy the body used (Coskun, 2022).

The same glucagon activity drives the liver results. In a Phase 2a study of fatty liver disease (MASLD), liver fat fell by about 81 to 82% at the two highest doses after 24 weeks (Sanyal, 2024). Glucagon makes the liver burn fat and make less of it, so the liver is where the effect is easiest to measure.

The Phase 3 TRIUMPH-1 results (Jastreboff, 2026) confirmed the size of effect seen in Phase 2, and the TRIUMPH-Outcomes trial is testing whether the three-receptor design changes heart results. Until it is approved, retatrutide stays an investigational compound, which is why it sits in the research category and not the pharmacy.

Why "Tirzepatide vs Mounjaro" and "Tirzepatide vs Ozempic" Are Slightly Wrong Questions

Many searches ask "tirzepatide vs Mounjaro" or "tirzepatide vs Ozempic". The first is not really a comparison: tirzepatide is the active ingredient in Mounjaro, so it compares a molecule with its own brand-name product. The real difference is between tirzepatide studied as a research peptide and Mounjaro as a finished prescription drug.

"Tirzepatide vs Ozempic" is a real comparison, because Ozempic is semaglutide. That is a dual agonist against a single agonist, and in head-to-head trials the dual agonist gives the larger effect. For all three in one place, see the retatrutide vs tirzepatide vs semaglutide comparison.

Sourcing Research-Grade Retatrutide

Because retatrutide is investigational, quality control is entirely on the supplier, and the only signals that matter are verifiable. For any research peptide, the checklist is the same: third-party HPLC analysis, a published certificate of analysis tied to the specific batch, and confirmed 99 percent-plus purity. If a vendor cannot produce a batch-matched COA, the material should be treated as unverified. Our how to verify research peptide purity COA guide walks through reading an HPLC report line by line.

Lyze Labs publishes a COA for every batch, with all material third-party HPLC tested to 99 percent-plus purity, and is trusted by researchers in 150+ countries, with 10,000+ orders shipped. Each kit is ten vials from one batch. Orders paid before the daily batch closes are processed that day, shipping is free and tracked, most orders arrive in 7 to 14 days, and delivery is guaranteed.

Frequently Asked Questions

Is retatrutide the same as Mounjaro or Ozempic?

No. Mounjaro is the approved drug tirzepatide, and Ozempic is the approved drug semaglutide. Retatrutide (LY3437943) is a separate three-receptor molecule that is not yet approved. It is supplied as a research peptide for laboratory study only and is not a substitute for any approved medicine.

What is the difference between retatrutide vs Mounjaro at the mechanism level?

Mounjaro contains tirzepatide, which switches on the GLP-1 and GIP receptors. Retatrutide adds a third target, the glucagon receptor. In research, that glucagon activity is linked to higher energy use and large drops in liver fat, which is the main difference between the two.

How does retatrutide vs Ozempic compare in research data?

Ozempic is semaglutide, which switches on one receptor (GLP-1). Retatrutide switches on three. In Phase 3, retatrutide 12 mg cut body weight by 25.0% at 80 weeks, while semaglutide 2.4 mg (the Wegovy dose) cut it by 14.9% at 68 weeks in its own pivotal trial. These are clinical-trial figures, not dosing advice.

Is tirzepatide vs Mounjaro even a valid comparison?

Not really, because tirzepatide is the active ingredient in Mounjaro. The useful difference is between tirzepatide studied as a research peptide and Mounjaro as a finished, approved prescription drug. The molecule is the same; the legal status and intended use are completely different.

Why is retatrutide sold as a research peptide instead of a drug?

Retatrutide has not been approved by the FDA. Its main Phase 3 trials are done, and Lilly plans to file for approval in early 2027. Until it is approved it cannot be sold as a medicine, so it is supplied for laboratory research, where scientists study its three-receptor mechanism and its effects on metabolism.

How do I verify the quality of research-grade retatrutide?

Look for three things: a batch-specific certificate of analysis, third-party HPLC testing, and confirmed 99 percent-plus purity. A supplier that publishes a COA tied to the exact batch you receive is giving you verifiable proof of identity and purity. Material without batch-matched documentation should be treated as unverified.

Order Research-Grade Retatrutide

For laboratory research into triple-agonist mechanisms, buy retatrutide with a published, batch-matched COA, third-party HPLC verification, and 99 percent-plus purity. A person confirms your order and sends payment options, day or night: card, PayPal, Apple Pay, Google Pay, bank transfer, local wallets or crypto.

Studies Cited

• Coskun T, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism.
• Jastreboff AM, et al. (2026). Retatrutide, a triple hormone receptor agonist, for treatment of obesity. New England Journal of Medicine.
• Sanyal AJ, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine.
• Aronne LJ, et al. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine.
• Lincoff AM, et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine.